US · Healthcare · Medical Devices
EPS came in at -0.40 against a street estimate of -0.38 — a miss of 5.3%.
Analysts rate Establishment Labs Holdings Inc a strong buy (7 buy, 1 hold, 0 sell out of 8) with an average price target of $95.33.
| Fund | Stake |
|---|---|
| JW Asset Management, LLC | 10.40% |
| RTW INVESTMENTS, LLC | 9.02% |
| Brown Advisory Holdings Inc | 5.19% |
| Tyro Capital Management LLC | 3.91% |
| Findell Capital Management LLC | 3.39% |
| BAMCO Inc | 3.28% |
| Nantahala Capital Management, LLC | 2.83% |
| Mudita Advisors LLP | 2.60% |
| Document | Date |
|---|---|
| Board / officer change · Q2 2026 | 2026-06-29 |
| Shareholder vote results · Q2 2026 | 2026-05-22 |
| Quarterly report · Q1 2026 | 2026-05-08 |
| Results announced · Q2 2026 | 2026-05-06 |
| Material agreement · Q2 2026 | 2026-04-30 |
| Proxy statement · Q2 2026 | 2026-04-10 |
| Annual report FY2025 | 2026-02-27 |
| Quarterly report · Q3 2025 | 2025-11-07 |
Readable in the app.
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Establishment Labs Holdings Inc — free to start.
Google PlayApp StoreData updated 2026-08-05.